Luxembourg BioHealth Cluster

The Luxembourg BioHealth Cluster is a young emerging Cluster aiming to reinforce and capitalise on the National Strategy developed by the Government to achieve scientific excellence in molecular diagnostics, the cornerstone of personalised medicine, and to enhance the Grand Duchy's reputation as a recognised and attractive environment for biomedical research, development, innovation (RDI) and business.

Our members are R&D companies, public research organisations, laboratories, hospitals and other actors (patients associations, providers of capital and services…) based in Luxembourg whose activities are related to Health Sciences and Technologies. With a principal focus on molecular diagnostics, the Cluster’s umbrella also covers other RDI/business domains that are key elements in an integrated patient-based personalised medicine approach, such as new therapeutics, bioinformatics, medical device and telemedicine. Supporting this dynamic and steadily growing biocommunity is our main objective. Therefore, we provide our members with a portfolio of added-value activities and servicesto supportthem in their daily RDI and/or business challenges and to increase their national and international visibility.

Opportunities

News

For the 7th consecutive year, Universal Biotech launches the call for proposal to valorise the most innovative projects in the healthcare industry. The Innovation Prize awards young start-ups (< 8 years) and academic research groups working on projects concerning drugs, medical devices, medical technologies and e-health solutions.

Anorexia has the highest mortality rate of all psychological and eating disorders. Where established therapies fail, alternative treatments such as deep brain stimulation are often successful, as illustrated by the Director of the Department of Functional Neurosurgery from Shanghai Ruijin Hospital, Bomin Sun at a multidisciplinary UniGR workshop involving both medical practitioners and researchers from the Greater Region and (far) beyond.

Epileptic encephalopathies are a severe form of epilepsies in children that often go together with developmental and intellectual problems. Within the European EuroEPINOMICS framework, LCSB researchers Dr Patrick May and Dr Roland Krause have contributed to the discovery of a new gene called KCNA2 that underlies this epilepsy syndrome in children. The results of this study have been published in the latest edition ofNature Genetics (doi:10.1038/ng.3239).